Last reviewed · How we verify
Trimetazidine 35 mg
At a glance
| Generic name | Trimetazidine 35 mg |
|---|---|
| Also known as | Vastarel MR |
| Sponsor | Beni-Suef University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients (PHASE3)
- Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy (PHASE1, PHASE2)
- Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients (PHASE4)
- Efficacy of Trimetazidine in Diabetic Patients (PHASE2)
- Trimetazidine as an Adjunct to Enhance Clopidogrel Response. (PHASE2)
- The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension (PHASE2, PHASE3)
- Trimetazidine in Myocardial Injury After Percutaneous Coronary Intervention in Patients With Angina and Diabetes (PHASE3)
- Trimetazidine in Pulmonary Artery Hypertension (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trimetazidine 35 mg CI brief — competitive landscape report
- Trimetazidine 35 mg updates RSS · CI watch RSS
- Beni-Suef University portfolio CI